Table 2:

Mean, SD, and percentage difference relative to controls of brain MRS metabolite ratios in 3 patients with and 3 patients without COVID-19a

SubjectNo. VoxelsNAA/CrbCho/CrbmI/CrbGlx/CrbLac/Crc
COVID-A70.61 ± 0.13 (−85%)d0.65 ± 0.05 (+80%)d1.17 ± 0.07 (+39%)d1.46 ± 0.20 (+51%)d0.76 ± 0.1
COVID-B81.10 ± 0.15 (−33%)d0.54 ± 0.04 (+63%)d1.16 ± 0.09 (+38%)d1.40 ± 0.13 (+47%)d0
COVID-C61.47 ± 0.08 (−5%)0.27 ± 0.03 (−4%)1.23 ± 0.10 (+44%)d1.04 ± 0.22 (+18%)0
DPL80.81 ± 0.11 (−62%)d0.48 ± 0.02 (+53%)d1.09 ± 0.05 (+32%)d1.82 ± 0.14 (+71%)d
SAE70.95 ± 0.16 (−47%)d0.32 ± 0.04 (+13%)0.61 ± 0.06 (−26%)1.10 ± 0.12 (+23%)0
Control61.54 ± 0.170.28 ± 0.040.79 ± 0.040.87 ± 0.07
  • a Positive and negative percentages between parentheses indicate percentage difference compared to the control subject.

  • b Data measured on short-TE (TE = 30 ms) spectra.

  • c Data measured on long-TE (TE = 288 ms) spectra. No long-TE spectra were available for the DPL and control cases.

  • d Percentage differences of >30% in magnitude. The distribution of these metabolite ratio derangements in patients with COVID-A (leukoencephalopathy) and COVID-B (post-cardiac arrest) is similar to that of the patient with DPL.